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Abstract
Inflammation is a necessary albeit insufficient component of tumorigenesis in some cancers.
Infectious agents directly implicated in tumorigenesis have been shown to induce inflammation. This
process involves both the innate and adaptive components of the immune system which contribute
to tumor angiogenesis, tumor tolerance and metastatic properties of neoplasms. Recently, heat-
shock proteins have been identified as mediators of this inflammatory process and thus may
provide a link between infection-mediated inflammation and subsequent cancer development. In
this review, the role of heat-shock proteins in infection-induced inflammation and carcinogenesis
will be discussed.
Introduction
Since the time of Rudolf Ludwig Karl Virchow, inflamma-
tion has been implicated as a necessary albeit insufficient
component in tumorigenesis in some cancers [1,2].
Recent research has characterized several molecular mech-
anisms that demonstrate such a link. In addition, numer-
ous infectious agents have been directly implicated as the
source of this inflammatory pathway. Studies have shown
that the innate and adaptive immune systems that
respond to these infections may be directly responsible for
tumor angiogenesis, tumor tolerance and in some cases
metastatic mechanisms by providing the tumor with
cytokines that promote these processes. One of the more
recent discoveries has been the role of heat-shock proteins
as mediators of this immune-mediated process via tumor
peptide presentation [3]. In this review, we will discuss
briefly the anti-cancer properties of heat-shock proteins
and emphasize their critical faculties in infection-medi-
ated inflammation-dependent tumorigenesis.
An estimated 10.9 million new cases of cancer occurred in
2002 worldwide. In 1990 investigators at the Interna-
tional Agency for Research on Cancer estimated that
approximately 9% of cancers in the United States and
20% of cancers in developing countries could be attrib-
uted to infectious agents [4]. This geographic disparity
may be due to the higher prevalence of cancer-related
infectious agents in developing countries [5]. Cancers
caused by such infections theoretically occur as a result of
direct cell targeting with subsequent tumor suppressor
gene inactivation, as in human papilloma virus (HPV),
prolonged local inflammation by bacteria residing out-
side of tumor cells, such as H. pylori, or immune suppres-
sion by viral agents, such as human immunodeficiency
virus [6-8]. Conversely, in the 1700s cancer patients who
cleared bacterial infections occasionally experienced
remission of their established malignancies [9]. In the late
1800s, Dr. William B. Coley of the New York Cancer
Center noted the regression of sarcoma in patients who
Published: 30 January 2009
Journal of Hematology & Oncology 2009, 2:5 doi:10.1186/1756-8722-2-5
Received: 15 December 2008
Accepted: 30 January 2009
This article is available from: http://www.jhoonline.org/content/2/1/5
© 2009 Goldstein and Li; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 10
(page number not for citation purposes)
Journal of Hematology & Oncology 2009, 2:5 http://www.jhoonline.org/content/2/1/5developed erysipelas [10]. Despite these isolated findings,
the preponderance of evidence shows that infections con-
tribute to carcinogenesis rather than counter it. A compre-
hensive explanation of this relationship has yet to be
described.
Inflammation, tumor immunity and tumorigenesis
Inflammation is a localized protective response elicited by
injury or destruction of tissues which serves to destroy,
dilute or wall off both the injurious agent and the injured
tissue. The inflammatory response to infections as well as
other stimuli involves a myriad of defenses, including
both the innate and adaptive arms of the immune system.
The innate immune system is comprised of myeloid cells
such as macrophages and dendritic cells, and innate lym-
phocytes such as natural killer cells, all of which lack
immunologic memory. This cellular component of the
innate immune system can either kill engulfed microbes
using toxins including superoxide anion, hydroxyl radical
and nitric oxide or process antigens in a MHC-dependent
manner. Extracellular antigens such as bacterial toxins are
presented by MHC class II on antigen presenting cells
(APCs) to CD4+ T cells whereas intracellular antigens
such as viral antigens are presented by MHC class I to
CD8+ T cells [11]. These APCs are stimulated by germline-
encoded innate receptors such as Toll-like receptors
(TLRs) to program adaptive immunity (both cellular and
humoral immunity) via cytokines, co-stimulatory mole-
cules in addition to present antigens to T cells [12].
The immune system therefore can function to modulate
tumorigenic pathogen-induced chronic inflammatory
responses or to identify and eliminate tumor cells. The lat-
ter process now known as immunologic tumor surveillance
was first proposed by Burnet in 1957 [13]. When these
events result in tumor clearance, it is known as elimination.
If not cleared, a state of equilibrium between the tumor-
suppressive immune system and tumor growth can occur.
If tumor immunoediting progresses, the tumor grows or
escapes [14,15]. Tumor immunologists in the past several
decades have been focusing on the immune system to
counter cancer. Increasing evidence is uncovering the par-
adoxical roles of the immune system to promote tumori-
genesis.
The ancient Roman physician Galen (129 – 199 C.E.) was
the first to posit the causal relationship between cancer
and inflammation. In 1863, the "Father of Pathology,"
Rudolf Virchow perpetuated the notion that cancers must
be due to prolonged irritation of various sorts. Similarly,
Dr. C. Heitzman declared in 1883 that the "so-called
small cellular infiltration [of Virchow] of the connective
tissue was the 'pre-stage of cancer"' [16]. Since that time,
the study of inflammation has become increasingly com-
plicated, albeit more cohesive, in its associations with can-
cer [17]. Ultimately, chronic inflammation has been
shown to contribute to tumorigenesis by causing DNA
damage, promoting neoangiogenesis and compromising
tumor immunosurveillance mechanisms.
Free radicals are thought to mediate tumorigenesis in the
context of inflammation. Excess oxidative/nitrosative
stress results in the generation of reactive oxygen species
(ROS) such as hydroxyl radicals (OH·) and ultimately the
accumulation of protein peroxidation, DNA damage and
lipid peroxidation (LPO) (Figure 1) [18]. ROS and reac-
tive nitrogen species (RNS) can damage both nuclear and
mitochondrial DNA, RNA, lipids and proteins by nitra-
tion, oxidation and halogenation reactions, leading to an
increased mutation load [19]. The LPO products [trans-4-
hydroxy-2-nonenal (HNE), 4-hydroperoxy-2-nonenal
(HPNE), and malondialdehyde (MDA)] can drift far from
Growth and inhibitory effects of free radicals on tumorsFigure 1
Growth and inhibitory effects of free radicals on 
tumors. The unchecked production of hydroxyl radicals and 
other reactive oxygen species (ROS) leads to protein and 
lipid peroxidation as well as DNA damage which increase 
mutation load resulting in either tumor regression or tumor 
progression. In response to intracellular protozoa, classically-
activated macrophages produce nitric oxide (NO) from 
arginine (L-arg) using the iNOS enzyme. H.pylori disinhibits 
iNOS in the gastric mucosa by attenuating the expression of 
HSP70 and HSP27. Tumor-associated macrophages (TAM) 
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potentially promutagenic if not removed [20].
In human lung bronchial epithelial cells, the proinflam-
matory cytokine TNF-α has been shown to induce produc-
tion of such ROS with a concomitant increase in 8-oxo-
deoxyguanosine, a marker for oxidative DNA damage. The
source of the ROS was shown to be spermine oxidase [21].
In vivo humans and experimental animals have been
found to harbor carcinogenic N-nitrosamines formed by
the deamination of DNA bases by N2O3 [22].
In the case of colon cancer, commensal intestinal flora can
activate TLRs on the luminal surface of intestinal epithe-
lial cells [23]. This interaction activates intracellular IKK-β
and ultimately NF-κB, the key regulator of inflammation
found in many solid tumors [24]. NF-κB is a homo- or
hetero-dimeric transcription factor of the Rel family. NF-
κB activates genes involved in cell proliferation (e.g., c-
myc, cyclins), as well as cell survival (e.g., c-FLIP, c-IAP1,
c-IAP2, XIAP, Bcl-XL, Bfl-1/A1 and p53) [25]. NF-κB con-
tributes unevenly to the pro-apoptotic and anti-apoptotic
pathways dependent upon its role in homeostasis or
tumor development, respectively [26]. In a pro-inflamma-
tory state, NF-κB contributes to the activation of COX-2,
iNOS and matrix metalloproteinase (MMP-9). Further-
more, NF-κB is responsible for the expression of adhesion
molecules and cell-surface metalloproteases, including
MMP-9 and MMP-2, substances which degrade the extra-
cellular matrix (ECM) to allow for metastases [27,28].
Downstream of NF-κB, increased expression of pro-
inflammatory COX-2 has been demonstrated in colorectal
adenomatous polyps and has been linked to the induc-
tion of tumorigenic DNA damage [18].
The tumor microenvironment features an important
inflammatory cell component as well. Currently, it is
believed that there are three types of activated macro-
phages. The classically activated macrophage which
responds to intracellular pathogens is stimulated by IFN-
γ, stimulates T-cells with IL-12, and produces nitric oxide
(NO) from arginine using the iNOS2 enzyme (Figure 1).
The so-called alternatively activated macrophages are
stimulated by IL-4, fail to make NO, and inhibit T cell pro-
liferation, but are able to produce IL-1-receptor antagonist
and IL-10. The type 2-activated macrophages induce TH2-
type humoral immune responses to antigen, such as IL-10
generation which results in IL-4 production by T cells, and
leads to an anti-inflammatory milieu [29].
One key inflammatory component to tumor sustenance
first discovered in the late 1970s is the infiltration of
tumor-associated macrophages (TAM) which are attracted
by monocyte chemotactic protein (MCP-1), RANTES and
CCL5. TAMs accumulate in poorly vascularized and rela-
tively hypoxic zones of tumor where hypoxia-inducible
factors (HIF-1 and HIF-2) predominate and promote
expression of pro-angiogenic VEGF, bFGF, and CXCL8
[30-34]. Like type 2-activated macrophages, TAMs release
IL-10, PGE-2, TGF-β and other cytokines that inhibit anti-
gen presentation and normal DC activity [35]. They are
not cytotoxic for tumor cells because of their limited pro-
duction of NO and proinflammatory cytokines and due to
the production of IL-10 which dampens cytotoxic T-cell
reactivity [36,37]. The Sea squirt-derived trabectidin has a
selective cytotoxic effect on TAMs by binding to the minor
groove of DNA and reducing IL-6 production, resulting in
tumor growth suppression [38].
When functioning in concert, these processes may prevent
adequate immunosurveillance. As proof of principle, Luo
et al demonstrated that a legumain-based DNA vaccine
induced a robust CD8+ T cell response against TAMs, dra-
matically reducing their presence in tumor tissues and
decreasing proangiogenic TGF-β, TNF-α, MMP-9 and
VEGF. Subsequently, tumor angiogenesis, tumor growth
and metastases were suppressed [39].
Heat-shock proteins
First discovered accidentally in 1962 by Ritossa et al and
isolated in 1974 by Tissieres et al, heat-shock proteins
(HSPs) are a highly conserved group of protein products
generated as a result of natural stressors, such as fever and
active commensal gut microflora, or non-natural stres-
sors, such as hyperthermia, NSAIDS, aspirin, nutrient
withdrawal, ROS, proteasome inhibition, UV radiation
and chemotherapy-induced DNA damage [40,41]. They
promote cell survival by preventing mitochondrial outer
membrane permeabilization, cytochrome c release, cas-
pase activation and apoptosome assembly [42]. HSPs
assist in general protein folding to prevent non-specific
aggregation of misfolded or unfolded proteins which
would otherwise be rendered nonfunctional. This folding
process is facilitated by cofactors such as Hsp70/Hsp90
Organizing Protein (HOP) which associates with Hsp70
and Hsp90 to mediate the transfer of polypeptides from
Hsp70 to Hsp90. Conversely, Hsp70 and Hsp90 may
associate with the ubiquitin ligase CHIP and lead to pro-
teasomal degradation of a misfolded protein.
Highly inducible HSPs such as HSP70 and HSP27 are
transcriptionally controlled by heat shock transcription
factor trimers, such as hsf1. For example, hsf1 represses
transcription when bound to HSP70 during attenuation
of the heat shock response as a negative feedback mecha-
nism [43]. In a normal host, hsf1 enhances organismal
survival and longevity. In cancer, however, hsf1 in partic-
ular has been found to be overexpressed and to contribute
to invasion and metastasis by permitting increased cell
proliferation and by decreasing cell death [44-47]. AsPage 3 of 10
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experimental tumors [48].
HSP activation can directly affect both innate and adap-
tive immunity, although controversial studies and opin-
ions exist in the field [49-51]. The innate immune
responses induced by HSPs include cytokine and chemok-
ine release by professional APCs and T-cells, maturation
of DCs by upregulating the expression of costimulatory
and antigen-presenting molecules such as B7-1, B7-2 and
MHC-II molecules, induction of migration of DC to
draining lymph nodes and activation of NK cells [52].
For example the HSP gp96 interacts with TLR2/4 resulting
in the activation of NF-κB-driven reporter genes and
mitogen- and stress-activated protein kinases. Gp96 also
induces the degradation of IκBα in DCs while simultane-
ously stimulating both the innate and adaptive immune
system [53]. Gp96-activated DCs release proinflamma-
tory cytokines resulting in the induction of an inflamma-
tory response by the innate component of the immune
system [54]. Necrotic tumor cell-derived mammalian
gp96 and hsp70 signal APCs via CD14, TLRs and CD91
(Figure 2) [55-58]. Tumor-derived Hsp70 can also activate
NK cells having a high cell surface density of CD94 [59]
by inducing NKG2D ligands on the surface of DCs [60].
This scenario may be particularly relevant in melanoma
which overexpresses Hsp70.
The immunogenic potential of gp96-peptide complexes
was first demonstrated by Srivastava et al [61,62]. When
manipulated, tumor-derived gp96 vaccine induces T cell
priming and tumor rejection [63-65]. When HSP-peptide
complexes are procured by APCs, peptide is transferred
from HSPs to MHC molecules for recognition by T cells
[61]. Dai et al found that cell surface expression of gp96
leads to the priming and maintenance of both CD4+ and
CD8+ T cell immunity against tumors and potentiates
cross-presentation of intracellular antigens to MHC-I for
activation of CD8+ T cells [66]. The interaction of gp96
with DCs leads to the preferential expansion of antigen-
specific CD8+ T cells in vitro and in vivo in a TLR4-
dependent manner [67]. These CD8+ T cells can then con-
tribute to tumor immunosurveillance.
Furthermore, HSPs have been shown to induce T cell reg-
ulation of chronic inflammation [68]. HSPs can chaper-
one both steroid and non-steroid hormone receptors.
Interestingly, steroids can interact with HSP-bound gluco-
corticoid receptors and increase the expression of IκBα,
preventing the nuclear translocation of the pro-inflamma-
tory molecule NF-κB [69,70].
Heat-shock proteins and tumorigenesis
The histologic evidence of chronic inflammation resulting
from an infection is insufficient to explain a tumorigenic
mechanism. This shortcoming can partially be reconciled
by the identification of HSPs in and around tumors (Fig-
ure 3). Heat-shock proteins can be produced by tumors,
microbes, and even inflammatory cells in the tumor
microenvironment. Only recently have HSPs been impli-
cated as biochemical elements of both anti-tumor immu-
nity [3] and oncogenesis [48].
Unique HSPs activated in cancer cells have been well-doc-
umented and correlated with tumor cell proliferation, dif-
ferentiation, invasion, metastasis and prognosis.
Frequently, the tumor-derived HSPs are acetylated [71]
and cannot be directly compared with native HSP or
microbial HSP. Gp96 from tumor cells demonstrate
greatly altered glycosylation patterns compared to host
cell gp96, which may elucidate deficiencies in immune
surveillance [72]. Tumor-derived Hsp90 can rescue wild
type proteins as well as unstable mutant proteins impli-
cated in carcinogenesis. Moreover, tumor-derived HSP90
is present entirely in multi-chaperone complexes with
high ATPase activity, unlike non-tumor HSP90 [73,74].
For example, in chronic lymphocytic leukemia (CLL),
ZAP-70+ lymphocytes express activated HSP90 which
binds and stabilizes ZAP-70 with several HSP co-chaper-
ones [75].
The HSP90 family consists of cytoplasmic HSP90β, induc-
ible α-form, GRP94/gp96 and mitochondrial TRAP1/
Heat-shock protein signal cascadeFigure 2
Heat-shock protein signal cascade. Necrotic tumor-
derived mammalian gp96 and HSP70 can signal antigen-pre-
senting cells (APCs) via CD14, and other receptors such as 
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one that assists in folding of signature tumorigenic pro-
teins such as HER-2/ErbB2, Akt, Raf-1, v-Src, and Bcr-Abl
[76]. HSP90 is overexpressed in a wide variety of solid and
hematologic malignancies and correlates with a poor
prognosis [77]. The expression of endoplasmic reticulum
regulator HSP70-member GRP78 (also known as BiP),
glucose-regulated protein GRP94/gp96, or HSP90 has
been associated significantly with vascular invasion and
intrahepatic metastasis [78]. HSP90 may even promote
invasion of metastases by chaperoning NF-kB-dependent
MMP-2 [79].
Cultured cells and transgenic mice have been shown to
exhibit cellular transformation and tumor formation
when forced to over express intracellular HSP27 or HSP70
[80-83]. It has even been proposed that by interacting
with mutant p53 and various oncogene products such as
pp60-v-src, fes and fgr, these HSPs may alter cell cycle reg-
ulation and contribute to the anti-apoptotic mechanism
of tumorigenesis [84].
HSP70 belongs to a family of inducible chaperone pro-
teins frequently present on the plasma membrane of
colon, lung, pancreas and breast cancer metastases [85].
This ATP-dependent chaperone can be induced by a vari-
ety of stimuli, including chemotherapy. HSP70 is a pow-
erful anti-apoptotic protein that reduces caspase
activation and suppresses mitochondrial damage and
nuclear fragmentation [86]. HSP70 can even subvert
apoptosis by blocking the translocation of Bax, which
results in stabilization of the outer mitochondrial mem-
brane [87]. HSP70 is also a potent activator of the human
complement system in an antibody-independent fashion
[88]. In defense, cancer cells block complement-mediated
killing by expressing membrane complement regulatory
proteins, such as CD46, CD55, CD35 and CD59 [89].
HSP27 of the inducible small HSP family has been shown
to inhibit the mitochondrial release of SMAC (second
mitochondrial-derived activator of caspase), the master
regulator of apoptosis, to confer resistance of multiple
myeloma cells to dexamethasone [90]. Conford et al have
found a high correlation between the level of HSP27
expression and the Gleason score in prostate cancer [91].
HSP40, HSP60, and HSP70 expressions are up-regulated
in response to the development of high grade intraepithe-
lial neoplasia and cervical cancer [92]. These examples
begin to unveil the complex relationship between HSPs
and cancer formation.
Microbes, inflammation, heat-shock proteins and cancer
The parasitic origin of cancer was originally suggested by
Paget in 1887 [93].
"I believe that microbe parasites, or substances produced
by them, will some day be found in essential relation with
cancer and cancerous disease."
In 1913, Dr. Johannes Fibiger, the pathological anatomist
in Copenhagen, produced numerous cancers in the fore-
stomach of rats by feeding them a nematode taken from
the muscles of a cockroach [94]. Similarly, Bullock and
Curtis produced hepatic sarcomas in rats by feeding them
tapeworm eggs from cats [95]. And Schistosoma, a para-
sitic trematode or fluke discovered in 1851 by Theodor
Bilharz, has been shown to cause chronic local inflamma-
tion which seems to increase the risk of developing squa-
mous cell bladder cancer [96]. Over 200 million people in
tropical and subtropical countries are believed infected by
any of six species of schistosomes. In Egypt alone, 27% of
the 2500 new cancer patients each year have bladder can-
cers attributed to schistosomiasis [97].
Adult schistosome trematodes are found in the venous
plexus around the urinary bladder. Any eggs released can
then traverse the bladder wall and cause hematuria.
Immune responses during the early stages of schisto-
somiasis infection are directed against antigens of schisto-
somula, and demonstrate a TH1 profile. With the onset of
egg laying, TH1 responses are replaced by vigorous TH2
responses directed against egg antigens. The result is a tis-
Venn diagram demonstrating a model of the tumorigenic relationship betwee  infection, chronic inflammation andmicrob l- or host-deriv d he t-sh ck prot insFigure 3
Venn diagram demonstrating a model of the tumori-
genic relationship between infection, chronic inflam-
mation and microbial- or host-derived heat-shock 
proteins.Page 5 of 10
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trate of TH2 cells, eosinophils, macrophages and
fibroblasts within a dense collagen-rich matrix. Schisto-
some-induced macrophages and neutrophils are impor-
tant sources of endogenous oxygen or hydroxyl radicals,
which are also implicated in the formation of carcino-
genic N-nitrosamines [98]. These inflammatory cells may
induce genotoxic effects, such as mutations, sister chro-
matid exchanges and DNA strand breaks [99-101]. They
may also participate in the activation of procarcinogens,
such as aromatic amines and polycyclic aromatic hydro-
carbons, generating carcinogenic metabolites [102]. An
increased number of inflammatory cells in the urinary
bladder of schistosomal patients may enhance the carci-
nogenic potential of these agents by increasing their rate
of activation. Furthermore, in patients with S. haemato-
bium and bladder cancer, TAMs attracted to the bladder
can produce TNF alpha, a key component of inflamma-
tion which is upregulated by HSP60 and HSP90.
HSP can be produced by a wide variety of parasitic organ-
isms as detailed by Maresca et al [103]. HSP86, HSP70,
HSP60, HSP58, HSP27 have all been detected in S. man-
soni. In superficial transitional cell bladder cancer, the loss
of surface expression of tumor-derived HSP60 and HSP90
was correlated with a poor prognosis, possibly explained
by the inability of T cells and NK cells to recognize these
tumor cells [104]. In the future these findings may cham-
pion parasite-derived HSPs as potential carcinogens.
Bacteria have also been implicated as a cause of cancer. In
1893, Bizzozero discovered a spirochete in the stomach of
dogs. This finding has since been verified by numerous
scientists including Salomon in 1896 and Krienitz in 1906
who related a similar finding to gastric cancer in a human
patient [105]. More importantly, in 1983 the microbe
now known as Helicobacter pylori was identified as a trig-
ger of gastric cancer and gastric lymphoma [106-108]. H.
pylori is associated with infiltration by neutrophils and
mononuclear cells in gastric mucosa, likely attracted by
granulocyte macrophage colony-stimulating factor and
RANTES. Subsequently macrophages and monocytes
respond to the presence of H. pylori via TLR2 resulting in
NF-κB activation and the release of early proinflammatory
cytokines, such as IL-1β. Macrophage-derived migration
inhibitory factor (MIF) is a potent cytokine produced by
H. pylori that overrides tumor suppressor p53 activity by
suppressing its transcriptional activity. The result is
increased DNA damage by inflammatory cells [109]. Fur-
thermore, H. pylori infection disinhibits iNOS (Figure 1)
in the presence of lipopolysaccharide by significantly
attenuating the expression of HSP70 and HSP27 [110]. As
expected, increased iNOS expression and subsequent oxi-
dative damage has been found in gastric mucosa chroni-
cally infected with H. pylori [111].
Corresponding increases in various cytokines including
IL-1β, IL-6, IL-8, and TNF-α have also been identified
[112]. Investigators have shown that H. pylori must
directly contact the host cell in order to up-regulate IL-8
[113]. NF-κB-dependent expression of IL-8 has been cor-
related with increased vascularity in human gastric carci-
nomas [114]. Takenaka et al have demonstrated how H.
pylori-derived HSP60 can activate NF-κB and mitogen-
activated protein kinase (MAPK) and induce IL-8 produc-
tion and secretion through TLR-2 and TLR-4 pathways in
KATO III human gastric epithelial cells [115,116]. HSP62,
a member of the HSP60 chaperonin family and homo-
logue of the H. pylori HSP known as GroEL, has been
shown to participate in the extracellular assembly of H.
pylori -derived urease, a known virulence factor [117].
These mechanisms provide insight into the relationship
between H. pylori infection, inflammation, HSPs and tum-
origenesis.
Chlamydial HSP60 has also been recognized as a poten-
tial extracellular stimulus of oncogenesis in that it is
found in pre-neoplastic lesions and can bind TLRs, induc-
ing a cascade of signaling which leads to neoangiogenesis,
macrophage activation and anti-apoptosis mediated by
complexing with Bax and Bak [118]. However, there is
limited evidence which can implicate microbial or host
HSPs as directly carcinogenic.
Parasites and bacteria are not the only culprits. In 1911,
Dr. Peyton Rous of the Rockefeller Institute first demon-
strated the RNA retrovirus causally associated with sarco-
mas in chickens for which he received the Nobel Prize in
1966 [119]. Since then several human cancers have been
attributed to viral infections although the exact mecha-
nism has not been elucidated in every case.
In 1963, Blumberg discovered the Hepatitis B virus
(HBV), which is now known to cause hepatocellular carci-
noma (HCC) in humans. Cell surface expression of viral
HBsAg and HBcAg in association with MHC class I mole-
cules activates CD8+ cytotoxic T lymphocytes which can
then produce IFN-gamma. Hepatic GRP94/gp96, an
endoplasmic reticulum-associated member of the HSP90
family, has been observed in association with HBV DNA
and core antigen protein in biopsies of HCC [120,121].
Hepatic gp96 expression has been correlated with the
degree of tumor differentiation and tumor size [120]. The
exact role of gp96 in this case has not been determined.
Interestingly, expression of the SMAC-inhibitor HSP27
has been shown to correlate with prognosis, disease-free
and overall survival in patients with HBV-associated HCC
[122].
The Epstein-Barr virus (EBV) is highly prevalent in
humans (≥ 90% worldwide are carriers). In 1964, EpsteinPage 6 of 10
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phoma in Central Africa, a highly aggressive but poten-
tially curable form of non-Hodgkin lymphoma, as well as
nasopharyngeal carcinoma. EBV is able to bind CD21 on
B cells, a critical event to the induction of HSPs and the
transformation of some B cells enabling them to become
independent of the usual regulatory factors, including T
cells. Cheung et al described in detail the coordinate
induction of HSP70 and HSP90 at mRNA and protein lev-
els upon EBV infection in vitro. Induction of HSPs and
transformation of B cells were dependent on EBV-induced
trans-membrane Ca2+ currents, but not on EBV gene
products. Blockade of HSP induction prevented transfor-
mation [123]. This evidence has been essential for deci-
phering the role of HSPs in tumorigenesis.
Conclusion
For over two millennia scientists have speculated the eti-
ology of cancer. In some instances such as tobacco use,
there is a preponderance of evidence demonstrating a
direct carcinogenic link with tobacco use. The roles of
chronic infections and chronic inflammation have been
repeatedly investigated as tumorigens for over a century
with only a handful of confirmed associations relative to
the diversity of human neoplasms and pathogens. Never-
theless, the worldwide population burden of infectious
organisms makes understanding their role in human dis-
ease of paramount importance to cancer prevention strat-
egies. Molecular studies have been able to dissect the
pathophysiology of carcinogenesis on many levels. The
direct and indirect involvement of microbial or host heat-
shock proteins in the malignant transformation of a
chronically infected host has been shown to be integral.
This review attempts to assemble the evidence implicating
heat-shock proteins in the neoplastic process.
Ever since the crucial role of heat shock proteins in cancer
pathophysiology was established, efforts to inhibit their
carcinogenic capacity have taken many forms. Heat-shock
protein vaccines using conjugated tumor peptides
[124,125] and direct HSP90 inhibitors such as 17-
(Allylamino)-17-demethoxygeldanamycin (17-AAG) [76]
have been investigated in clinical trials. Currently these
interventions have not proven efficacy clinically, although
they seem promising in vitro and in early phase trials. It
remains to be seen whether or not manipulation of one
HSP at a time will lead to meaningful tumor responses
and/or survival benefit.
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